Chemours (CC) Q3 2026 Earnings Call Transcript

Chemours reported Q3 net sales of $1.54 billion, up 3% year over year, and adjusted EBITDA of $200 million at the high end of guidance; adjusted EPS rose to $0.21 from $0.17. Performance Solutions sales grew 26%, and AI infrastructure exposure reached 10% of company sales, while weaker demand pressured TSS and broader titanium markets. Chemours expects 2026 adjusted EBITDA of $775 million-$800 million and about 2% net sales growth, but lowered free-cash-flow conversion guidance to 15%-20%, citing restricted cash, settlements, taxes and working-capital timing; net leverage was 4.3x at quarter-end.

Analysis

The key tension is earnings quality versus cash realization: pricing and mix supported EBITDA, but litigation-related payments, restricted cash and working-capital timing weaken near-term cash conversion. At 4.3x net leverage, weaker cash generation matters more to equity optionality than a single quarter’s adjusted EPS; asset-sale proceeds and debt prepayments help, but do not establish a durable deleveraging path. Verify the settlement payment schedule, restricted-cash release terms and year-end net debt before treating the leverage target as secured.

AI is a credible growth option, not yet a basis for underwriting a step-change in value. The 10% sales exposure spans TSS and APM and is not a disclosed profit contribution. Management also described persistent demand exceeding its ability to catch up in APM, while the higher Q4 outlook partly reflects pent-up orders and operational recovery. Watch shipment conversion, capacity/turnaround execution and customer qualification; a 2027 two-phase cooling architecture remains a possibility, not a committed adoption timetable.

TT pricing is supporting margins against weak regional volumes, but that makes price retention—not reported price increases—the pivotal 1–3 month test. Imports, trade actions and producer restarts could undermine discipline. TSS’s Q4 decline appears substantially seasonal and compares against prior channel fill; the better read on aftermarket normalization arrives toward late Q1 2027. Over 6–18 months, AI cooling and higher-value APM mix could improve the portfolio, but litigation cash demands and leverage constrain how much of that upside accrues to equity. The contrarian risk is assuming AI sales growth translates quickly into incremental free cash flow.

Key Decisions for Investors

• Do not chase CC solely on the AI/cooling narrative. Keep exposure neutral-to-underweight pending valuation context and evidence that APM order strength converts to shipped volume, margins and cash—not just a larger order book.
• For a relative-value expression, consider a small, catalyst-driven CC underweight versus a diversified chemicals basket, rather than an unhedged short. Reassess after Q4 cash-flow and debt disclosures; reduce the underweight if operating cash flow improves without relying on asset sales and net leverage falls as guided.
• Over the next 1–3 months, monitor TT price realization versus volume, Q4 TSS seasonality, APM turnaround/working-capital needs, and actual litigation cash payments. Price erosion or continued weak volumes alongside missed EBITDA guidance would strengthen the cautious view; sustained pricing and cash conversion would falsify it.
• Treat late-Q1 2027 TSS aftermarket restocking and customer adoption of liquid-cooling products as alerts, not current catalysts to capitalize. Verify capacity, qualification and product-level economics before assigning material earnings value to the potential two-phase transition.